Urolithin A and Mitophagy
Urolithin A is a gut‑metabolite of ellagitannins, first identified as a potent inducer of mitophagy in preclinical models, leading to a targeted supplement program. · Extensive studies by Chris Rinsch, Patrick Aebischer, and colleagues at Amazentis / Timeline, spanning 18 years of translational research. (2008)
Urolithin A is a postbiotic compound that triggers mitophagy, the selective clearance of damaged mitochondria, and has shown benefits for muscle function and endurance in clinical trials.
Core Concepts
The Problem
Mitochondrial dysfunction accumulates with age and contributes to sarcopenia, metabolic decline, and reduced healthspan.
The Claim
Oral supplementation with urolithin A can activate mitophagy and improve muscle health and cellular resilience in aging humans.
Key Evidence
- •Multiple randomized controlled trials in humans showing improved mitochondrial gene expression and muscle performance.
Practical Implication
Targeting mitophagy may be a viable strategy to extend healthspan and reduce age‑related decline.
Nuance & Limits
Urolithin A’s effects may depend on individual capacity to produce it naturally from diet; supplementation standardizes the dose.
Source Material
Citation Density
Growing clinical evidence, but not yet independently replicated by multiple research groups outside the company.
Related Ideas
Urolithin A is a specific intervention that supports mitochondrial quality control, a core pillar of mitochondrial health.
Gaps
- ⚠ Long‑term outcome data on lifespan extension in humans is lacking; most studies are on muscle function.
Discuss Further
Open this concept in an AI assistant for deeper discussion, critique, or exploration.